Nurona-NT Tablet is a combination pharmaceutical formulation containing Gabapentin 400 mg and Nortriptyline 10 mg, indicated for the management of neuropathic pain and certain types of chronic pain disorders. Gabapentin, an anticonvulsant, modulates calcium channels to inhibit excitatory neurotransmitter release, thereby reducing neuronal hyperexcitability associated with neuropathic pain. Nortriptyline, a tricyclic antidepressant, enhances noradrenergic and serotonergic neurotransmission by inhibiting the reuptake of norepinephrine and serotonin, contributing to analgesic effects and mood stabilization. This synergistic combination is particularly effective in patients with diabetic neuropathy, postherpetic neuralgia, and other neuropathic conditions where monotherapy has proven insufficient. Nurona-NT is administered orally, with dosage tailored according to clinical response and tolerability. Common adverse effects may include dizziness, somnolence, dry mouth, and gastrointestinal disturbances; patients should be monitored for signs of central nervous system depression and anticholinergic effects. Caution is advised in individuals with a history of cardiac arrhythmias, glaucoma, or renal impairment. Nurona-NT should be used under strict medical supervision, with gradual dose adjustments to minimize withdrawal symptoms and optimize therapeutic outcomes. This combination therapy offers a comprehensive approach to neuropathic pain management by targeting multiple pathophysiological mechanisms.